Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection

Autores
Artman, Chad; Idegwu, Nnebuefe; Brumfield, Kyle D.; Lai, Ken; Hauta, Shirley; Falzarano, Darryl; Parreño, Gladys Viviana; Yuan, Lijuan; Geyer, James D.; Goepp, Julius G.
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: Human norovirus (HuNoV) is the leading viral cause of diarrhea, with GII.4 as the predominant genotype of HuNoV outbreaks globally. However, new genogroup variants emerge periodically, complicating the development of anti-HuNoV vaccines; other prophylactic or therapeutic medications specifically for HuNoV disease are lacking. Passive immunization using oral anti-HuNoV antibodies may be a rational alternative. Here, we explore the feasibility of using avian immunoglobulins (IgY) for preventing HuNoV infection in vitro in a human intestinal enteroid (HIE) model. Methods: Hens were immunized with virus-like particles (VLP) of a GII.4 HuNoV strain (GII.4/CHDC2094/1974/US) by intramuscular injection. The resulting IgY was evaluated for inhibition of binding to histo-blood group antigens (HBGA) and viral neutralization against representative GII.4 and GII.6 clinical isolates, using an HIE model. Results: IgY titers were detected by three weeks following initial immunization, persisting at levels of 1:221 (1:2,097,152) from 9 weeks to 23 weeks. Anti-HuNoV IgY significantly (p < 0.05) blocked VLP adhesion to HBGA up to 1:12,048 dilution (0.005 mg/mL), and significantly (p < 0.05) inhibited replication of HuNoV GII.4[P16] Sydney 2012 in HIEs up to 1:128 dilution (0.08 mg/mL). Neutralization was not detected against genotype GII.6. Conclusions: We demonstrate the feasibility of IgY for preventing infection of HIE by HuNoV GII.4. Clinical preparations should cover multiple circulating HuNoV genotypes for comprehensive effects. Plans for animal studies are underway.
Fil: Artman, Chad. No especifíca;
Fil: Idegwu, Nnebuefe. No especifíca;
Fil: Brumfield, Kyle D.. University of Maryland; Estados Unidos
Fil: Lai, Ken. University of Saskatchewan; Canadá
Fil: Hauta, Shirley. University of Saskatchewan; Canadá
Fil: Falzarano, Darryl. University of Saskatchewan; Canadá
Fil: Parreño, Gladys Viviana. Instituto Nacional de Tecnología Agropecuaria. Centro de Investigación en Ciencias Veterinarias y Agronómicas. Instituto de Virología e Innovaciones Tecnológicas. - Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Yuan, Lijuan. Virginia-Maryland College of Veterinary Medicine; Estados Unidos
Fil: Geyer, James D.. University of Alabama at Birmingahm; Estados Unidos
Fil: Goepp, Julius G.. No especifíca;
Materia
CALICIVIRUS
FOODBORNE DISEASE
GASTROENTERITIS OUTBREAKS
IGY
NOROVIRUS
OUTBREAK PREVENTION AND CONTROL
PASSIVE IMMUNOTHERAPY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/210369
Acceder
id CONICETDig_fe94ef064ac26efbe508319b3226b360
oai_identifier_str oai:ri.conicet.gov.ar:11336/210369
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus InfectionArtman, ChadIdegwu, NnebuefeBrumfield, Kyle D.Lai, KenHauta, ShirleyFalzarano, DarrylParreño, Gladys VivianaYuan, LijuanGeyer, James D.Goepp, Julius G.CALICIVIRUSFOODBORNE DISEASEGASTROENTERITIS OUTBREAKSIGYNOROVIRUSOUTBREAK PREVENTION AND CONTROLPASSIVE IMMUNOTHERAPYhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Background: Human norovirus (HuNoV) is the leading viral cause of diarrhea, with GII.4 as the predominant genotype of HuNoV outbreaks globally. However, new genogroup variants emerge periodically, complicating the development of anti-HuNoV vaccines; other prophylactic or therapeutic medications specifically for HuNoV disease are lacking. Passive immunization using oral anti-HuNoV antibodies may be a rational alternative. Here, we explore the feasibility of using avian immunoglobulins (IgY) for preventing HuNoV infection in vitro in a human intestinal enteroid (HIE) model. Methods: Hens were immunized with virus-like particles (VLP) of a GII.4 HuNoV strain (GII.4/CHDC2094/1974/US) by intramuscular injection. The resulting IgY was evaluated for inhibition of binding to histo-blood group antigens (HBGA) and viral neutralization against representative GII.4 and GII.6 clinical isolates, using an HIE model. Results: IgY titers were detected by three weeks following initial immunization, persisting at levels of 1:221 (1:2,097,152) from 9 weeks to 23 weeks. Anti-HuNoV IgY significantly (p < 0.05) blocked VLP adhesion to HBGA up to 1:12,048 dilution (0.005 mg/mL), and significantly (p < 0.05) inhibited replication of HuNoV GII.4[P16] Sydney 2012 in HIEs up to 1:128 dilution (0.08 mg/mL). Neutralization was not detected against genotype GII.6. Conclusions: We demonstrate the feasibility of IgY for preventing infection of HIE by HuNoV GII.4. Clinical preparations should cover multiple circulating HuNoV genotypes for comprehensive effects. Plans for animal studies are underway.Fil: Artman, Chad. No especifíca;Fil: Idegwu, Nnebuefe. No especifíca;Fil: Brumfield, Kyle D.. University of Maryland; Estados UnidosFil: Lai, Ken. University of Saskatchewan; CanadáFil: Hauta, Shirley. University of Saskatchewan; CanadáFil: Falzarano, Darryl. University of Saskatchewan; CanadáFil: Parreño, Gladys Viviana. Instituto Nacional de Tecnología Agropecuaria. Centro de Investigación en Ciencias Veterinarias y Agronómicas. Instituto de Virología e Innovaciones Tecnológicas. - Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Yuan, Lijuan. Virginia-Maryland College of Veterinary Medicine; Estados UnidosFil: Geyer, James D.. University of Alabama at Birmingahm; Estados UnidosFil: Goepp, Julius G.. No especifíca;MDPI2022-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/210369Artman, Chad; Idegwu, Nnebuefe; Brumfield, Kyle D.; Lai, Ken; Hauta, Shirley; et al.; Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection; MDPI; Viruses; 14; 11; 11-2022; 1-151999-4915CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3390/v14112371info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:59:14Zoai:ri.conicet.gov.ar:11336/210369instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:59:14.648CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection
title Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection
spellingShingle Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection
Artman, Chad
CALICIVIRUS
FOODBORNE DISEASE
GASTROENTERITIS OUTBREAKS
IGY
NOROVIRUS
OUTBREAK PREVENTION AND CONTROL
PASSIVE IMMUNOTHERAPY
title_short Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection
title_full Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection
title_fullStr Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection
title_full_unstemmed Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection
title_sort Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection
dc.creator.none.fl_str_mv Artman, Chad
Idegwu, Nnebuefe
Brumfield, Kyle D.
Lai, Ken
Hauta, Shirley
Falzarano, Darryl
Parreño, Gladys Viviana
Yuan, Lijuan
Geyer, James D.
Goepp, Julius G.
author Artman, Chad
author_facet Artman, Chad
Idegwu, Nnebuefe
Brumfield, Kyle D.
Lai, Ken
Hauta, Shirley
Falzarano, Darryl
Parreño, Gladys Viviana
Yuan, Lijuan
Geyer, James D.
Goepp, Julius G.
author_role author
author2 Idegwu, Nnebuefe
Brumfield, Kyle D.
Lai, Ken
Hauta, Shirley
Falzarano, Darryl
Parreño, Gladys Viviana
Yuan, Lijuan
Geyer, James D.
Goepp, Julius G.
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv CALICIVIRUS
FOODBORNE DISEASE
GASTROENTERITIS OUTBREAKS
IGY
NOROVIRUS
OUTBREAK PREVENTION AND CONTROL
PASSIVE IMMUNOTHERAPY
topic CALICIVIRUS
FOODBORNE DISEASE
GASTROENTERITIS OUTBREAKS
IGY
NOROVIRUS
OUTBREAK PREVENTION AND CONTROL
PASSIVE IMMUNOTHERAPY
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Background: Human norovirus (HuNoV) is the leading viral cause of diarrhea, with GII.4 as the predominant genotype of HuNoV outbreaks globally. However, new genogroup variants emerge periodically, complicating the development of anti-HuNoV vaccines; other prophylactic or therapeutic medications specifically for HuNoV disease are lacking. Passive immunization using oral anti-HuNoV antibodies may be a rational alternative. Here, we explore the feasibility of using avian immunoglobulins (IgY) for preventing HuNoV infection in vitro in a human intestinal enteroid (HIE) model. Methods: Hens were immunized with virus-like particles (VLP) of a GII.4 HuNoV strain (GII.4/CHDC2094/1974/US) by intramuscular injection. The resulting IgY was evaluated for inhibition of binding to histo-blood group antigens (HBGA) and viral neutralization against representative GII.4 and GII.6 clinical isolates, using an HIE model. Results: IgY titers were detected by three weeks following initial immunization, persisting at levels of 1:221 (1:2,097,152) from 9 weeks to 23 weeks. Anti-HuNoV IgY significantly (p < 0.05) blocked VLP adhesion to HBGA up to 1:12,048 dilution (0.005 mg/mL), and significantly (p < 0.05) inhibited replication of HuNoV GII.4[P16] Sydney 2012 in HIEs up to 1:128 dilution (0.08 mg/mL). Neutralization was not detected against genotype GII.6. Conclusions: We demonstrate the feasibility of IgY for preventing infection of HIE by HuNoV GII.4. Clinical preparations should cover multiple circulating HuNoV genotypes for comprehensive effects. Plans for animal studies are underway.
Fil: Artman, Chad. No especifíca;
Fil: Idegwu, Nnebuefe. No especifíca;
Fil: Brumfield, Kyle D.. University of Maryland; Estados Unidos
Fil: Lai, Ken. University of Saskatchewan; Canadá
Fil: Hauta, Shirley. University of Saskatchewan; Canadá
Fil: Falzarano, Darryl. University of Saskatchewan; Canadá
Fil: Parreño, Gladys Viviana. Instituto Nacional de Tecnología Agropecuaria. Centro de Investigación en Ciencias Veterinarias y Agronómicas. Instituto de Virología e Innovaciones Tecnológicas. - Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Yuan, Lijuan. Virginia-Maryland College of Veterinary Medicine; Estados Unidos
Fil: Geyer, James D.. University of Alabama at Birmingahm; Estados Unidos
Fil: Goepp, Julius G.. No especifíca;
description Background: Human norovirus (HuNoV) is the leading viral cause of diarrhea, with GII.4 as the predominant genotype of HuNoV outbreaks globally. However, new genogroup variants emerge periodically, complicating the development of anti-HuNoV vaccines; other prophylactic or therapeutic medications specifically for HuNoV disease are lacking. Passive immunization using oral anti-HuNoV antibodies may be a rational alternative. Here, we explore the feasibility of using avian immunoglobulins (IgY) for preventing HuNoV infection in vitro in a human intestinal enteroid (HIE) model. Methods: Hens were immunized with virus-like particles (VLP) of a GII.4 HuNoV strain (GII.4/CHDC2094/1974/US) by intramuscular injection. The resulting IgY was evaluated for inhibition of binding to histo-blood group antigens (HBGA) and viral neutralization against representative GII.4 and GII.6 clinical isolates, using an HIE model. Results: IgY titers were detected by three weeks following initial immunization, persisting at levels of 1:221 (1:2,097,152) from 9 weeks to 23 weeks. Anti-HuNoV IgY significantly (p < 0.05) blocked VLP adhesion to HBGA up to 1:12,048 dilution (0.005 mg/mL), and significantly (p < 0.05) inhibited replication of HuNoV GII.4[P16] Sydney 2012 in HIEs up to 1:128 dilution (0.08 mg/mL). Neutralization was not detected against genotype GII.6. Conclusions: We demonstrate the feasibility of IgY for preventing infection of HIE by HuNoV GII.4. Clinical preparations should cover multiple circulating HuNoV genotypes for comprehensive effects. Plans for animal studies are underway.
publishDate 2022
dc.date.none.fl_str_mv 2022-11
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/210369
Artman, Chad; Idegwu, Nnebuefe; Brumfield, Kyle D.; Lai, Ken; Hauta, Shirley; et al.; Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection; MDPI; Viruses; 14; 11; 11-2022; 1-15
1999-4915
CONICET Digital
CONICET
url http://hdl.handle.net/11336/210369
identifier_str_mv Artman, Chad; Idegwu, Nnebuefe; Brumfield, Kyle D.; Lai, Ken; Hauta, Shirley; et al.; Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection; MDPI; Viruses; 14; 11; 11-2022; 1-15
1999-4915
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.3390/v14112371
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613759176278016
score 13.260194

Publicaciones similares